Analyst Price Targets — ZBH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 10, 2026 11:26 am | Caitlin Cronin | Canaccord Genuity | $100.00 | $96.55 | TheFly | Zimmer Biomet price target raised to $100 from $83 at Canaccord |
| August 6, 2026 5:13 pm | — | Truist Financial | $106.00 | $96.62 | TheFly | Zimmer Biomet price target raised to $106 from $92 at Truist |
| August 6, 2026 1:27 pm | — | Robert W. Baird | $104.00 | $97.32 | TheFly | Zimmer Biomet price target raised to $104 from $92 at Baird |
| August 6, 2026 12:44 pm | Patrick Wood | UBS | $120.00 | $97.06 | TheFly | Zimmer Biomet price target raised to $120 from $115 at UBS |
| August 6, 2026 12:09 pm | — | Bernstein | $93.00 | $97.53 | TheFly | Zimmer Biomet price target raised to $93 from $91 at Bernstein |
| August 6, 2026 11:28 am | — | BMO Capital | $96.00 | $98.16 | TheFly | Zimmer Biomet price target raised to $96 from $95 at BMO Capital |
| August 6, 2026 11:16 am | Kendall Au | RBC Capital | $110.00 | $98.16 | TheFly | Zimmer Biomet price target raised to $110 from $101 at RBC Capital |
| July 28, 2026 10:32 am | Patrick Wood | UBS | $115.00 | $92.07 | TheFly | Zimmer Biomet upgraded to Buy from Sell at UBS |
| July 8, 2026 8:25 pm | — | BMO Capital | $95.00 | $87.56 | TheFly | Zimmer Biomet initiated with a Market Perform at BMO Capital |
| April 29, 2026 1:52 pm | — | Truist Financial | $92.00 | $80.80 | TheFly | Zimmer Biomet price target lowered to $92 from $98 at Truist |
Latest News for ZBH
Zimmer Biomet is seeing structural constant currency sales growth appear. This is driven by transformation factors, R&D and M&A efforts. Earnings growth is lagging sales, but this hopefully should catch up soon.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
WARSAW, Ind., Aug. 28, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2026.
ZBH's growth outlook is backed by healthy procedure demand and Z1, HAMMR and OrthoGrid adoption, though debt and competition remain concerns.
Zimmer Biomet (NYSE: ZBH) reported second-quarter 2026 net sales of $2.177 billion, up 4.8% on a reported basis and 4.0% on an organic constant-currency basis, as growth in hips, specialty businesses and technology helped offset weaker performance in certain other product lines. U.S. organic constant-currency sales rose 4.6%, while international sales increased 3.1%. Chairman, President and
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.